

氏名	所属	職名	取得学位	専門分野	主な論文・著作・業績
寺崎 一典	高エネルギー 医学研究部門	准教授	博士(医学)	核薬学 放射線薬品学 分子イメージング	<p>①Ono Y, Yosuke Akamatsu Y, Araya S, Yamazaki R, Fujiwara S, Chida K, Masakazu Kobayashi M, Koji T, Terasaki K, Ogasawara K. Clinical features and treatment outcomes in patients in their twenties with ischemic moyamoya disease. <i>Cerebrovasc Dis Extra.</i> 14(1):105-115(2024)</p> <p>②Ogasawara K, Takahashi T, Igarashi S, Yabuki M, Omori D, Akamatsu Y, Chida K, Kobayashi M, Fujiwara S, Terasaki K. Effect of the addition of <math>^{123}\text{I}</math>-iomazenil single-photon emission computed tomography to brain perfusion single-photon emission computed tomography on the detection accuracy of misery perfusion in adult patients with ischemic moyamoya disease. <i>Ann Nucl Med.</i> 37(5):280-288(2023)</p> <p>③Kimura K, Kubo Y, Dobashi K, Katakura Y, Chida K, Kobayashi M, Yoshida K, Fujiwara S, Terasaki K, Kawamura T, Ogasawara K. Angiographic, Cerebral hemodynamic, and cognitive outcomes of indirect revascularization surgery alone for adult patients with misery perfusion due to ischemic moyamoya disease. <i>Neurosurgery.</i> 90(6):676-683(2022)</p> <p>④Igarashi S, Ando T, Takahashi T, Yoshida J, Kobayashi M, Yoshida K, Terasaki K, Fujiwara S, Kubo Y, Ogasawara K. Development of cerebral microbleeds in patients with cerebral hyperperfusion following carotid endarterectomy and its relation to postoperative cognitive decline. <i>J Neurosurg.</i> 1:1-7(2021)</p> <p>⑤Iwata R, Terasaki K, Ishikawa Y, Harada R, Furumoto S, Yanai K, Pascali C. A concentration-based microscale method for <math>^{18}\text{F}</math>-nucleophilic substitutions and its testing on the one-pot radiosynthesis of <math>[^{18}\text{F}]</math>FET and <math>[^{18}\text{F}]</math>fallypride. <i>Appl Radiat Isot.</i> 166:109361(2020)</p>
佐々木 敏秋	高エネルギー 医学研究部門	講師	博士(工学)	放射線科学 核医学	<p>①Beppu T, Iwaya T, Sato S, Nomura J, Terasaki K, Sasaki T, Yamada N, Fujiwara S, Sugai T, Ogasawara K. : PET with <math>^{11}\text{C}</math>-methyl-L-methionine as a predictor of consequential outcomes at the time of discontinuing temozolomide-adjuvant chemotherapy in patients with residual IDH-mutant lower-grade glioma/Clin Nucl Med. 47(7):569-574(2022)</p> <p>②Beppu T, Sato Y, Yamada N, Terasaki K, Sasaki T, Sugai T, Ogasawara K. : Impacts on histological features and <math>^{11}\text{C}</math>-methyl-L-methionine uptake after one-shot administration with bevacizumab before surgery in newly diagnosed glioblastoma/Transl Oncol. 12(11): 1480-1487(2019)</p> <p>③Beppu T, Sasaki T, Sato Y, Terasaki T. : High-uptake areas on <math>^{18}\text{F}</math>-FRP170 PET image necessarily include proliferating areas in glioblastoma : a superimposed image study combining <math>18\text{F}</math>-FRP170 PET with <math>^{11}\text{C}</math>-methionine PET/Advances in Molecular Imaging. 7:1-11(2017)</p> <p>④Beppu T, Terasaki K, Sasaki T, Sato Y, Tomabechi M, Kato K, Sasaki M, Ogasawara K. : MRI and <math>^{11}\text{C}</math>-methyl-L-methionine PET differentiate bevacizumab true responders after initiating therapy for recurrent glioblastoma/Clin Nucl Med. 41(11):852-857 (2016)</p> <p>⑤Beppu T, Sasaki T, Terasaki K, Saura H, Mtsuura H, Ogasawara K, Sasaki M, Iwata R, Takai Y. : High-uptake areas on positron emission tomography with the hypoxic radiotracer <math>^{18}\text{F}</math>-FRP170 in glioblastomas include regions retaining proliferative activity under hypoxia/Ann Nucl Med. 29:336-341(2015)</p>